About 100 reports

  • Stages of bladder cancer
  • Bladder cancer therapeutics market in Americas

About Bladder Cancer Therapeutics The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the...

  • Cancer
  • United States
  • World
  • Forecast
  • Merck & Co., Inc.
  • Cancer supportive care market in EMEA
  • 3.2 Information sources

About Cancer Supportive Care Cancer supportive care drugs are used for the treatment of adverse effects caused due to the cancer treatment such as chemotherapy-induced anemia, CINV, bone metastasis, cancer pain, and others. Various class of drugs are used as cancer supportive care drugs. Some of the major drug class that involves...

  • Cancer
  • Therapy
  • Amgen Inc.
  • Helsinn Group
  • Merck & Co., Inc.
  • COLORECTAL CANCER: KEY METRICS IN SEVEN MAJOR PHARMACEUTICAL MARKETS
  • MODERATE GROWTH IN THE COLORECTAL CANCER MARKET EXPECTED FROM 2015 THROUGH 2025

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased...

  • Cancer
  • Colorectal Cancer
  • Hospital
  • Therapy
  • Merck & Co., Inc.
  • LUNG CANCER THERAPEUTICS MARKET IN EMEA
  • MARKET PENETRATION OF VARIOUS LUNG CANCER THERAPEUTICS MANUFACTURERS IN GLOBAL (2015)

About Lung Cancer Therapeutics Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes...

  • Cancer
  • Lung Cancer
  • Therapy
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • 2.4.3 BIOMARKERS/TARGETS OF INTEREST
  • 8.1.4 KEY LICENSING DEALS

Genes & Diseases; ##(##): ##-## Cancer Network.

  • Cancer
  • Chemotherapy
  • Monoclonal Antibody
  • Therapy
  • Merck & Co., Inc.
  • Executive Summary
  • Untitled

Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19 Summary Cancer is anticipated to become increasingly prevalent due to aging populations and rising levels of obesity in the developed world. Cancer vaccines...

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.
  • 10.3 ADVAXIS
  • 10.26 ONCOTHYREON

© IGATE RESEARCH PAGE ## OF ## GLOBAL CANCER VACCINES MARKET - OVERVIEW The cancer industry is one of the most lucrative business worldwide.

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.
  • 9.1.3 INVESTIGATIONAL NEW DRUG/CLINICAL TRIAL AUTHORIZATION-FILED
  • Introduction

Cancer Letters; ##(##): ##-## Globocan (2012).

  • Cancer
  • Therapy
  • World
  • Market Size
  • Merck & Co., Inc.
  • Breast Cancer Therapeutics Market, Global, Co-development Deals in Southeast Asia and Deals with Disclosed Values, 2006-
  • Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase I, 2016

Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market Summary Breast cancer is a malignant neoplasm that begins in the breast tissue, which is made up of glands for milk production called lobules and the ducts that connect the lobules...

  • Cancer
  • Therapy
  • Southeast Asia
  • Market Size
  • Merck & Co., Inc.
  • Executive Summary
  • EARLY-STAGE CLINICAL DEVELOPMENT IN NSCLC

INTERNATIONAL JOURNAL OF CANCER; ##(##): ##-##.

  • Cancer
  • Hospital
  • Lung Cancer
  • Therapy
  • Merck & Co., Inc.
  • 8.1 References
  • UROLOGIC ONCOLOGY THERAPEUTICS MARKET, GLOBAL, FORECAST MARKET SHARE BY

Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics Summary Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer – the key indications covered...

  • Cancer
  • Therapy
  • Urology
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 9.1.4 PHASE I
  • 8.2.4 KEY CO-DEVELOPMENT DEALS

BMC Cancer; ##(##); ##-## Lubin JH, et al. (2004).

  • Cancer
  • Lung Cancer
  • Targeted Therapy
  • Therapy
  • Merck & Co., Inc.
  • 8.1 References
  • Oncology, Global, All Clinical Stage Pipeline Products, 2016

Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics Summary In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of...

  • Cancer
  • Clinical Trial
  • Oncology
  • Therapy
  • Merck & Co., Inc.
  • TREATING LUNG CANCER
  • Novel Therapies in Breast Cancer Treatment

This report, the World Market for Cancer Therapeutics presents a detailed picture of the market for cancer drugs, with a focus on novel therapies. The market analysis in this report includes analysis of products avaiable for each cancer type (Breast Cancer, Lung Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Colon Cancer and Other types)...

  • Cancer
  • Targeted Therapy
  • Therapy
  • Merck & Co., Inc.
  • Novartis AG
  • Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
  • Executive Summary

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies Summary Gastric cancer is characterized by the formation of malignant cells in the inner lining of the stomach, and is the fifth most common cancer globally. Due to its indolent nature it...

  • Cancer
  • Gastric Cancer
  • Therapy
  • Merck & Co., Inc.
  • Roche Group
  • Three major brands dominate the global cervical cancer market. A comparison of these brands is provided below.
  • Market landscape

About cervical cancer Cervical cancer is the abnormal growth of cancerous cells in the tissues of the cervix. It is the world's fourth most common cause of death in women. The disease can be classified as squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma originates in the lining of the cervix, while adenocarcinoma arises...

  • Cancer
  • Therapy
  • Vaccine
  • World
  • Merck & Co., Inc.
  • C) Treatment population
  • 8.1 BIBLIOGRAPHY

Cancer Discovery; ##(##): ##-## Hanahan D and Weinberg RA (2011).

  • Cancer
  • Cancer Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • Merck & Co., Inc.
  • KEY FINDINGS

Colorectal Cancer: Competitive Landscape to 2026 Report Code: GDHC##CL Published: April 2018 Healthcare TABLE OF CONTENTS ##.

  • Cancer
  • Colorectal Cancer
  • Array BioPharma Inc.
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • SEVERAL KEY EVENTS WILL DRIVE CHANGES TO THE BLADDER CANCER MARKET LANDSCAPE.
  • KOL INSIGHT ON THE UPDATES TO THE BLADDER CANCER COMPETITIVE LANDSCAPE (APRIL 2017-FEBRUARY 2018)

Bladder Cancer: Dynamic Market Forecast to 2026 Summary Bladder cancer is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the bladder cancer space, including...

  • Cancer
  • Vaccine
  • Market Size
  • Eli Lilly & Co.
  • Merck & Co., Inc.

Gastric cancer

4546 5000 3864
  • Pipeline: Gastric Cancer
  • Forecast: Gastric Cancer

Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer. This report addresses the following questions: - What impact will the PD-1/PD-L1 inhibitor class of drugs have on the gastric cancer market? - How will pipeline immunotherapies...

  • Cancer
  • Chemotherapy
  • Gastric Cancer
  • Therapy
  • Merck & Co., Inc.

One patient with a form of brain cancer called glioblastoma is already receiving the combined therapy.

  • Cancer
  • Specialty Hospital
  • Therapy
  • Merck & Co., Inc.
  • Merck Serono S.A.
  • KEY UPDATES IN ALKM+ NSCLC
  • Abbreviations

Event ##: Market Dynamics Shift in Frontline NSCLC ## ##.

  • Cancer
  • Lung Cancer
  • Therapy
  • AstraZeneca PLC
  • Merck & Co., Inc.

Head and neck cancer

4546 5000 3864

Nature Reviews Cancer, ##(##), ##-## < DOI> ##. ##/ nrc##< / DOI>.

  • Cancer
  • European Union
  • Japan
  • United States
  • Merck & Co., Inc.
  • 2 Bladder Cancer: Executive Summary
  • BLADDER CANCER: KEY METRICS IN THE 7MM

OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2025 Summary Bladder cancer is a urologic malignancy arising primarily from epithelial cells lining the bladder. In the vast majority of cases (>90%), bladder cancer manifests as transitional (urothelial) cell carcinoma (TCC). The remaining...

  • Bladder Cancer
  • Cancer
  • Therapy
  • Japan
  • Merck & Co., Inc.

Colorectal cancer

4546 5000 3864
  • LEADING TREATMENTS FOR COLORECTAL CANCER
  • LEADING TREATMENTS FOR COLORECTAL CANCER

Pipeline candidates for the colorectal cancer market will pursue novel mechanisms of action to distinguish themselves in an increasingly crowded market. This report addresses the following questions: - How are new therapies differentiating themselves in the increasingly crowded and price-sensitive CRC market? - How...

  • Cancer
  • Chemotherapy
  • Colorectal Cancer
  • Therapy
  • Merck & Co., Inc.
  • 11: Prescription Skin Cancer Drugs
  • COMMON PRESCRIPTION TOPICAL, INTRALESIONAL AND OTHER SKIN CANCER AGENTS

World Prescription Dermatological Drugs Market details the various categories of prescription dermatological drugs, describes the worldwide market for prescription dermatological drugs, and identifies major market factors that may help to shape the worldwide market for prescription dermatological drugs in the future.

  • Cancer
  • Dermatological Condition
  • Therapy
  • Market Size
  • Merck & Co., Inc.
  • Forecast: Triple-Negative Breast Cancer
  • Pipeline: Triple-Negative Breast Cancer

The aggressive nature of triple-negative breast cancer and a lack of targeted therapies creates opportunities for pipeline candidates to fulfil areas of high unmet need. This report addresses the following questions: - Which branded therapies will have the largest commercial potential in the triple-negative breast cancer...

  • Breast Cancer
  • Cancer
  • Targeted Therapy
  • Therapy
  • Merck & Co., Inc.
  • PANCREATIC CANCER THERAPEUTICS, GLOBAL, DEVELOPMENTAL PIPELINE, PHASE II, 2015
  • PANCREATIC CANCER THERAPEUTICS, GLOBAL, DEVELOPMENTAL PIPELINE, PHASE I, 2015

Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape Summary Pancreatic Cancer (PC) is a disease predominately of the elderly with ~75% of PC cases being diagnosed in patient’s over 75 years old. PC proliferates rapidly, is...

  • Cancer
  • Clinical Trial
  • Pancreatic Cancer
  • Therapy
  • Merck & Co., Inc.
  • PROSTATE CANCER THERAPEUTICS, GLOBAL, DEVELOPMENTAL PIPELINE, PHASE I, 2015
  • 8.1.1 PFIZER ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH MERCK

Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth Summary Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of...

  • Cancer
  • Prostate Cancer
  • World
  • Forecast
  • Merck & Co., Inc.
  • 7.2 ASTRAZENECA-RECENT DEVELOPMENTS

One of the major causes of cancer in Japan is smoking.

  • Cancer
  • Chemotherapy
  • Therapy
  • Amgen Inc.
  • Merck & Co., Inc.